S

Sage Therapeutics

D
SAGE
USD
0.32
(4.2161%)
Market Closed
28,546.00
Volume
-6.35
EPS
-
Div Yield
-1.067476
P/E
482,908,806.38
Market Cap
Today
4.2161%
1 Week
7.473%
1 Month
-9.600%
6 Months
-58.994%
12 Months
-61.339%
Year To Date
-63.447%
All Time
0%

Title:
Sage Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Do you need help or have a question?